Greenwich Lifesciences Inc Financials
This page shows Greenwich Lifesciences Inc (GLSI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Greenwich Lifesciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Greenwich Lifesciences Inc carries a low D/E ratio of 0.62, meaning only $0.62 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.
Greenwich Lifesciences Inc generates a -623.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -132.7% the prior year.
Greenwich Lifesciences Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Greenwich Lifesciences Inc generates $0.46 in operating cash flow (-$7.3M OCF vs -$15.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Greenwich Lifesciences Inc reported -$15.8M in net income in fiscal year 2024. This represents a decrease of 77.6% from the prior year.
Greenwich Lifesciences Inc earned $-1.21 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 75.4% from the prior year.
Cash & Balance Sheet
Greenwich Lifesciences Inc held $4.1M in cash against $0 in long-term debt as of fiscal year 2024.
Greenwich Lifesciences Inc had 13M shares outstanding in fiscal year 2024. This represents an increase of 2.4% from the prior year.
Margins & Returns
Greenwich Lifesciences Inc's ROE was -623.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 490.4 percentage points from the prior year.
Capital Allocation
Greenwich Lifesciences Inc invested $13.0M in research and development in fiscal year 2024. This represents an increase of 68.2% from the prior year.
GLSI Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.5M+0.4% | $3.5M+34.9% | $2.6M | N/A | $2.3M-0.7% | $2.3M+5.2% | $2.2M | N/A |
| SG&A Expenses | $653K+21.4% | $538K-21.0% | $681K | N/A | $437K+23.6% | $354K+3.2% | $343K | N/A |
| Operating Income | -$4.2M-3.2% | -$4.0M-23.3% | -$3.3M | N/A | -$2.7M-2.5% | -$2.7M-4.9% | -$2.5M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$4.2M-3.1% | -$4.0M-23.5% | -$3.3M | N/A | -$2.7M-2.4% | -$2.6M-5.4% | -$2.5M | N/A |
| EPS (Diluted) | $-0.300.0% | $-0.30-20.0% | $-0.25 | N/A | $-0.200.0% | $-0.20-5.3% | $-0.19 | N/A |
GLSI Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.8M+21.8% | $3.1M+13.6% | $2.8M-32.8% | $4.1M-29.7% | $5.8M-19.4% | $7.2M+31.2% | $5.5M-21.2% | $7.0M |
| Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $3.8M+21.8% | $3.1M+13.6% | $2.7M-32.8% | $4.1M-29.7% | $5.8M-19.4% | $7.2M+31.2% | $5.5M-21.2% | $7.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.6M-3.8% | $1.7M+17.2% | $1.4M-7.8% | $1.6M+85.2% | $842K-37.7% | $1.4M+247.3% | $390K+32.3% | $294K |
| Current Liabilities | $1.6M-3.8% | $1.7M+17.2% | $1.4M-7.8% | $1.6M+85.2% | $842K-37.7% | $1.4M+247.3% | $390K+32.3% | $294K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.2M+51.8% | $1.4M+9.7% | $1.3M-48.2% | $2.5M-49.1% | $5.0M-15.2% | $5.9M+14.7% | $5.1M-23.6% | $6.7M |
| Retained Earnings | -$77.6M-5.7% | -$73.4M-5.8% | -$69.4M-4.9% | -$66.2M-13.8% | -$58.1M-4.8% | -$55.4M-4.9% | -$52.8M-4.9% | -$50.4M |
GLSI Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M-19.6% | -$2.2M-21.7% | -$1.8M+1.0% | -$1.9M+28.3% | -$2.6M-146.6% | -$1.0M+41.2% | -$1.8M+17.3% | -$2.2M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $3.4M+28.6% | $2.6M+429.7% | $492K+304.2% | $122K-89.7% | $1.2M-57.3% | $2.8M+825.0% | $299K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
GLSI Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -190.0%+89.6pp | -279.6%-31.3pp | -248.3% | N/A | -53.6%-9.2pp | -44.4%+3.9pp | -48.3% | N/A |
| Return on Assets | -109.1%+19.7pp | -128.8%-10.3pp | -118.5% | N/A | -45.8%-9.8pp | -36.1%+8.8pp | -44.9% | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt-to-Equity | 0.74-0.4 | 1.17+0.1 | 1.10+0.5 | 0.62+0.4 | 0.17-0.1 | 0.23+0.2 | 0.08+0.0 | 0.04 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Greenwich Lifesciences Inc profitable?
No, Greenwich Lifesciences Inc (GLSI) reported a net income of -$15.8M in fiscal year 2024.
What is Greenwich Lifesciences Inc's return on equity (ROE)?
Greenwich Lifesciences Inc (GLSI) has a return on equity of -623.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Greenwich Lifesciences Inc's operating cash flow?
Greenwich Lifesciences Inc (GLSI) generated -$7.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Greenwich Lifesciences Inc's total assets?
Greenwich Lifesciences Inc (GLSI) had $4.1M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Greenwich Lifesciences Inc spend on research and development?
Greenwich Lifesciences Inc (GLSI) invested $13.0M in research and development during fiscal year 2024.
What is Greenwich Lifesciences Inc's debt-to-equity ratio?
Greenwich Lifesciences Inc (GLSI) had a debt-to-equity ratio of 0.62 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Greenwich Lifesciences Inc's return on assets (ROA)?
Greenwich Lifesciences Inc (GLSI) had a return on assets of -385.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Greenwich Lifesciences Inc's cash runway?
Based on fiscal year 2024 data, Greenwich Lifesciences Inc (GLSI) had $4.1M in cash against an annual operating cash burn of $7.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Greenwich Lifesciences Inc's Piotroski F-Score?
Greenwich Lifesciences Inc (GLSI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Greenwich Lifesciences Inc's earnings high quality?
Greenwich Lifesciences Inc (GLSI) has an earnings quality ratio of 0.46x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Greenwich Lifesciences Inc?
Greenwich Lifesciences Inc (GLSI) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.